OpenAI acquires Orchestra Bio to build AI agents that link scientific findings with drug development workflows. The deal expands OpenAI’s focus into pharma, enabling automated decision support for candidate selection and study design. This move positions OpenAI to accelerate drug discovery and integrate AI into the pharmaceutical pipeline.
Opening Kapyn…